Back to Search
KATHERINE SEIBERT, M.D.
M.D.
Internal Medicine Physician
NPI: 1982616991IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
133006(NY)
Education
CREIGHTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1976
Research & Publications (20)
Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
PMID 18457826·Eur J Pharmacol·2008
7-preclinical
Deficits in social behavior and reversal learning are more prevalent in male offspring of VIP deficient female mice.
PMID 18316078·Exp Neurol·2008
4-observational
Mechanistic implications in the Morita-Baylis-Hillman alkylation: isolation and characterization of an intermediate.
PMID 16568961·J Am Chem Soc·2006
8-other
Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
PMID 15494548·J Pharmacol Exp Ther·2005
7-preclinical
Unprecedented reactivity in the Morita-Baylis-Hillman reaction; intramolecular alpha-alkylation of enones using saturated alkyl halides.
PMID 16307141·Chem Commun (Camb)·2005
8-other
Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
PMID 12798067·J Orthop Res·2003
7-preclinical
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
PMID 12644588·Mol Pharmacol·2003
7-preclinical
Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants.
PMID 12124863·Arthritis Rheum·2002
4-observational
Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2.
PMID 12447834·Vet Ther·2002
7-preclinical
Pharmacology of celecoxib in rat brain after kainate administration.
PMID 12183639·J Pharmacol Exp Ther·2002
7-preclinical
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.
PMID 12051953·Prostaglandins Leukot Essent Fatty Acids·2002
6-review
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
PMID 11463341·Biochem J·2001
7-preclinical
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
PMID 11059745·Cancer Res·2000
7-preclinical
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
PMID 11016626·Cancer Res·2000
4-observational
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
PMID 10956225·J Med Chem·2000
7-preclinical
N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.
PMID 10794682·J Med Chem·2000
7-preclinical
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
PMID 10786667·Cancer Res·2000
7-preclinical
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
PMID 10728691·Cancer Res·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 23 LAKEWOOD AVE, HUDSON RIVER HEALTHCARE, INC.
MONTICELLO, NY 12701 - Phone
- (845) 794-2010
Quick Facts
- NPI
- 1982616991
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 50
- Publications
- 20
Are you this provider?
Claim Your Profile